Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions: A prospective pilot study

Oncology

Volumn 61, Issue 3, 2001, Pages 192-196

  Sartori, Sergio ^a   Nielsen, Ingrid ^a   Tassinari, Davide ^b   Trevisani, Lucio ^a   Abbasciano, Vincenzo ^a   Malacarne, Paolo ^a  

^a SANT ANNA HOSPITAL   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Interferon; Intracavitary treatment; Malignant ascites; Peritoneal effusions

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ABDOMINAL DRAINAGE; ADULT; AGED; ARTICLE; ASCITES; CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; EFFUSION; EVALUATION; FEMALE; HUMAN; MALE; OVARY CARCINOMA; PALLIATIVE THERAPY; PARACENTESIS; PATIENT MONITORING; PERITONEAL FLUID; PERITONEUM; PRIORITY JOURNAL; RECURRENT DISEASE; STANDARDIZATION; TREATMENT OUTCOME; ULTRASOUND;

ADULT; AGED; ASCITES; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM NEOPLASMS; DRAINAGE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INFUSIONS, PARENTERAL; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PAIN; PALLIATIVE CARE; PERITONITIS; PILOT PROJECTS; PROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME; VOMITING;

EID: 0035742687     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055374     Document Type: Article

References (28)

1. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients
2. Malignant ascites. A comparison of peritoneovenous shunting and nonoperative management
3. Peritoneovenous shunt for palliation of gynecologic malignant ascites
4. A new approach to the management of malignant ascites; a permanently implanted abdominal drain
5. Intracavitary bleomycin in the management of malignant effusions: A multicenter study
6. Malignant pleural effusion
7. Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma
8. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin
9. Intraperitoneal administration of interferon beta in ovarian cancer patients
10. Intracavitary beta-interferon for the management of pleural and/or peritoneal effusions in patients with advanced cancer refractory to chemotherapy
11. Treatment of malignant ascites due to recurrent/refractory ovarian cancer: The use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro
12. Local immunotherapy with interferon-α in metastatic pleural and peritoneal effusions: Correlation with immunologic parameters
13. Intracavitary bleomycin in the management of malignant effusions
14. Recombinant interferon alpha-2b in the management of malignant pleural effusions
15. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer
16. Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions
17. Intracavitary therapy of neoplastic effusions with cytokines: Comparison among interferon alpha, beta and interleukin-2
18. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: Role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo
19. The past, the present and future of the OK-432 therapy for patients with malignant effusions
20. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion
21. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion
22. Intraperitoneal interferon in the management of malignant ascites
23. Endocavitary beta-interferon in neoplastic effusions
24. Antitumor activity of gamma interferon in ascitic and solid tumor models of human ovarian cancer
25. Immunological effects of alternative weekly interferon-alpha and low dose interleukin-2 in patients with cancer
26. Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity
27. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy
28. Management of malignant pleural effusions